Roche offshoot Genentech
has announced the US$1.7
billion acquisition of Seragon
Pharmaceuticals, with the move
said to boost Roche’s pipeline of
potential cancer treatments.
Seragon has a portfolio of
experimental Oral Selective
Oestrogen Receptor Degraders
(SERDs) which target the treatment
of hormone receptor-positive
breast cancer.
Genentech will pay an initial
$725m in cash plus further
milestone payments of up to $1b.
Seragon was founded last
year as a spin-off of Aragon
Pharmaceuticals.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 14
OVER a quarter of a million people have sbeen vaccinated against influenza this year through community pharmacies in Queensland, reported the Pharmacy Guild of Australia.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.